ストックスクリーナーアプリを入手
12.88
6.62%
0.80
アフターアワーズ：
12.88
Eyepoint Inc (EYPT) 最新ニュース
New hires at EyePoint receive 39,700 stock options package - Stock Titan
(EYPT) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
EyePoint Pharmaceuticals Stock (US30233B1098): Analyst views and valuation in focus - AD HOC NEWS
EyePoint Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
EYPT: Phase III retinal drug aims for six-month dosing, rapid vision gains, and commercial readiness - TradingView
EyePoint outlines mid-2026 topline data target for DURAVYU in wet AMD and DME as Phase III trials advance - MSN
COMMODORE CAPITAL LP Increases Stake in EyePoint Inc - GuruFocus
JonesTrading Maintains EyePoint(EYPT.US) With Buy Rating, Maintains Target Price $43 - Moomoo
Earnings call transcript: Eyepoint Pharmaceuticals misses Q1 2026 EPS and revenue forecasts - Investing.com
(EYPT) Risk Channels and Responsive Allocation - Stock Traders Daily
EyePoint Pharmaceuticals eyes transformative 2026 as DURAVYU Phase 3 data nears - MSN
EYPT: DURAVYU nears pivotal phase III readouts, targeting reduced treatment burden and strong safety - TradingView
Commodore Capital (EYPT) discloses 4.25M-share, 5.1% stake in EyePoint - Stock Titan
EYPT News | EYEPOINT INC (NASDAQ:EYPT) - ChartMill
EyePoint (NASDAQ: EYPT) CFO exercises RSUs, uses shares to cover tax - Stock Titan
EyePoint Pharmaceuticals Eyes Transformative 2026 as DURAVYU Phase 3 Data Nears - Yahoo Finance
EYPT: DURAVYU's pivotal trial results are imminent, targeting six-month dosing and market differentiation - TradingView
EYPT: DURAVYU Phase III data expected in August, targeting six-month dosing and U.S. launch in 2025 - TradingView
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - 富途牛牛
(EYPT) Movement as an Input in Quant Signal Sets - Stock Traders Daily
EyePoint Inc. (EYPT) Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Advances PipelineAnnual Financial Report - The Legal Advocate
How The EyePoint (EYPT) Narrative Is Evolving With DURAVYU Trials And New Analyst Targets - Yahoo Finance
EyePoint Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
EyePoint Announces Participation at Upcoming Investor Conferences - The Manila Times
Should I Buy EYPT (EyePoint Pharmaceuticals, Inc.) | AI Analysis, Technical & News Insights - Kavout
EyePoint, Inc. Grants Stock Options to New Employees as Inducement Awards | EYPT Stock News - Quiver Quantitative
EyePoint hands new hires 158,100 stock options at $12.35 - Stock Titan
Assessing EyePoint (EYPT) Valuation After Recent Share Price Weakness - Yahoo Finance
[SCHEDULE 13G/A] EyePoint, Inc. Amended Passive Investment Disclosure - Stock Titan
EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data - Sahm
EyePoint’s DURAVYU Receives Third Consecutive Positive DSMC Review for Wet AMD - The Clinical Trial Vanguard
EyePoint Pharmaceuticals Says Phase 3 Eye Drug Trials Clear Safety Review - Moomoo
EyePoint (EYPT) Receives Positive Review for Duravyu Trials - GuruFocus
EyePoint Pharmaceuticals stock (US30233B1098): Phase 3 trials clear third safety review - AD HOC NEWS
EyePoint Announces Third Positive DSMC Review for DURAVYU Phase 3 Wet AMD Trials, Topline Data Expected Mid-2026 - Minichart
EyePoint's late-stage eye drug trials to continue after safety panel review - TradingView
EyePoint’s wet AMD trial continues after safety review By Investing.com - Investing.com Australia
Eyepoint announces third consecutive positive DSMC recommendation for phase 3 wet AMD trials for Duravyu(TM), building confidence ahead of mid-2026 topline data - marketscreener.com
EyePoint Advances DURAVYU Phase 3 Wet AMD Program - TipRanks
EyePoint’s wet AMD trial continues after safety review - Investing.com India
EyePoint receives third positive DSMC review; Phase 3 topline data on track for mid-2026 - TradingView
Third positive DSMC review backs EyePoint (EYPT) Phase 3 DURAVYU wet AMD trials - Stock Titan
Eyepoint Inc Announces Third Consecutive Positive Dsmc Recommendation for Phase 3 Wet Amd Trials for Duravyu - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
EyePoint: DURAVYU's Durability Could Drive Significant Upside (NASDAQ:EYPT) - Seeking Alpha
Adage Capital files amendment: 3,300,000 shares in EyePoint (EYPT) disclosed - Stock Titan
TradingKey - TradingKey
Liquidity Mapping Around (EYPT) Price Events - Stock Traders Daily
EyePoint Pharmaceuticals stock (US30233B1098): Trading at discount to fair value estimates - AD HOC NEWS
Mizuho Securities Reaffirms Their Buy Rating on EyePoint Pharmaceuticals (EYPT) - The Globe and Mail
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):